Back to Home
On-Demand Virtual Symposium

Assessing Utility of Anti-Vascular Endothelial Growth Factor Therapies in Retinal Disease: The Pharmacist’s Role From Access to Adherence, featuring a Patient Perspective

Release Date

October 17, 2023

Expiration Date

October 18, 2024

Credits

1.5 On-Demand

Topics

Ophthalmology/Optometry


This activity includes a Powered by Patients interview.

This activity was originally broadcast live at PTCE and Asembia Specialty Pharmacy Day of Education 2023.

Program Description
Retinal diseases including neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) pose a significant burden to patients and the health care system. In addition to time requirements for appointments for intravitreal injections of anti-vascular endothelial growth factor (VEGF) inhibitors and post-injection recovery, the cost of anti-VEGF therapies may limit patient access as well. Managed care professionals and pharmacists must ensure that retinal specialists and patients have access to a variety of anti-VEGF therapies so that treatment can be individualized. Specialty pharmacists are in a unique position to offer patient counseling expertise to patients on their retinal injections and provide an additional layer of ongoing treatment monitoring. This program will review the differentiating factors of available anti-VEGF therapies for nAMD and DME and emerging agents to equip pharmacists to ensure appropriate communication occurs with retinal specialists so that patients receive timely, effective, and comprehensive treatment. An included interview with a patient with nAMD/DME will shed light on the challenges in treatment and quality of life as well as their experience with medication access through collaboration with pharmacists involved in their care.

Target Audience: Specialty Pharmacist

Type of Activity: Application
Release date: October 17, 2023
Expiration date: October 17, 2024

Learner level: Foundational and intermediate

Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

  • Analyze the disease burden of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) and the impact on patient quality of life
  • Explain the mechanism of action, pharmacokinetics, and efficacy of anti-vascular endothelial growth factor (VEGF) agents in the treatment of nAMD and DME
  • Examine current clinical guidelines and recommendations for the use of anti-VEGF therapies in nAMD and DME
  • Identify opportunities for pharmacists to collaborate with other health care providers to improve access to care for patients with nAMD and DME, including addressing barriers to care such as cost, transportation, and lack of access to specialty providers
Assessing Utility of Anti-Vascular Endothelial Growth Factor Therapies in Retinal Disease: The Pharmacist’s Role From Access to Adherence, featuring a Patient Perspective

GET STARTED WITH THIS PROGRAM:

Register now to gain access to this program.

Create AccountAlready Registered? Login Here

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

What's Included
  • Access your activities anytime, anywhere, with a computer, tablet or smartphone
  • Free access with a PTCE account
  • Pharmacy education designed to improve patient care

Related Content

Course

Assessing Utility of Anti-Vascular Endothelial Growth Factor Therapies in Retinal Disease: The Pharmacist’s Role From Access to Adherence, featuring a Patient Perspective

Create Account